Yayınlar & Eserler

Yayın Ağı
Makaleler 133
Tümü (133)
SCI-E, SSCI, AHCI (103)
SCI-E, SSCI, AHCI, ESCI (110)
ESCI (7)
Scopus (112)
TRDizin (29)
Diğer Yayınlar (1)

1. Long-term outcomes of rare pure histological subtypes of breast cancer in a tertiary single-center retrospective cohort.

Fidan M. C., Guliyev M., Günaltılı M., Birsin Z., Çiçek E., Abbasov H., et al.
Discover oncology , 2026 (SCI-Expanded) identifier

2. Real-world comparison of androgen receptor pathway ınhibitors versus docetaxel as first-line treatment in metastatic hormone-sensitive prostate cancer.

Birsin Z., Aliyev V., Cebeci S., Guliyev M., Jeral Evinç S., Çerme E., et al.
Current medical research and opinion , ss.1-10, 2026 (SCI-Expanded, Scopus) identifier

3. Nutritional and inflammatory factors associated with chemotherapy response and survival in advanced high-grade serous ovarian cancer: A machine learning–based analysis.

Birsin Z., Cebeci S., Jeral S., Çerme E., Aliyev V., Demirci S. N., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.44, sa.16_suppl, ss.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

4. Burnout among caregivers of hospitalized medical oncology patients: A cross-sectional survey study.

Guzel S. S., Tay K., Demirci S. N., Alan Ö.
JOURNAL OF CLINICAL ONCOLOGY , cilt.44, sa.16_suppl, ss.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

5. Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature

Kıkılı C. İ., Araz M., Ürün Y., Başaran M., Şener N., Yazar A., et al.
CLINICAL GENITOURINARY CANCER , cilt.1, ss.1, 2026 (SCI-Expanded, Scopus)

6. Real-world outcomes of systemic therapy in patients with anaplastic thyroid carcinoma.

Alan Ö., Jeral S., Demirci S. N.
JOURNAL OF CLINICAL ONCOLOGY , cilt.44, sa.16_suppl, ss.1, 2026 (SCI-Expanded, Scopus) Creative Commons License

7. Prognostic Impact and Clinicopathological Correlates of HER2 Status in Gastric Cancer: A Multicenter Retrospective Turkish Oncology Group Study

Yildirim S., Sever O. N., Turkoglu E., Sariyar Busery N., Dogan A., Baydas T., et al.
CLINICAL MEDICINE INSIGHTS: ONCOLOGY , cilt.20, ss.1-23, 2026 (SCI-Expanded, Scopus) Creative Commons License

8. Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study

Mütiş Alan A., Murt A., Dinçer M. T., Trabulus S., Alan Ö., Altıparmak M. R.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.10, ss.1-16, 2026 (SCI-Expanded, Scopus) Creative Commons License

9. Prognostic Impact of PET/CT-Derived Sarcopenia in Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Cebeci S., Birsin Z., Jeral Evinç S., Abbasov H., Aliyev V., Çerme E., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.10, ss.1-18, 2026 (SCI-Expanded, Scopus) Creative Commons License

10. Immune-Mediated upper gastrointestinal toxicities reported With immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

Cerme E., Guliyev M., Aliyev V., Birsin Z., Günaltılı M., Fidan M. C., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.1, ss.1-8, 2026 (SCI-Expanded, Scopus)

11. Does Surgical Timing After Neoadjuvant Anti-HER2 Therapy Affect Pathological Complete Response and Survival in HER2-Positive Breast Cancer? A Multicenter Retrospective Cohort Study.

Birsine Z., Alkan O., Bükün H. O., Nazlı İ., Günaltılı M., Çerme E., et al.
Journal of surgical oncology , 2026 (SCI-Expanded, Scopus) identifier

12. Prognostic value of the pretreatment CA19-9/Albumin ratio in de novo metastatic colorectal cancer: A retrospective cohort study.

Günaltili M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Abbasov H., et al.
Medicine , cilt.105, sa.15, 2026 (SCI-Expanded, Scopus) identifier

13. Acute hemodialysis for cancer-associated acute kidney injury: etiologies, indications, and outcomes from a 25-year single-center experience

Mutis Alan A., Yalin S. F., Atas I., Alan Ö., Altiparmak M. R.
RENAL FAILURE , cilt.48, sa.1, ss.1-13, 2026 (SCI-Expanded, Scopus) Creative Commons License identifier

14. Prognostic value of nutritional and inflammation-based scores in advanced soft tissue sarcoma treated with trabectedin: a multicenter study

Jeral Evinç S., Eyüpler Akmercan Ç., Cebeci S., Birsin Z., Nazlı İ., Güren A. K., et al.
FRONTIERS IN ONCOLOGY , cilt.16, ss.1-10, 2026 (SCI-Expanded, Scopus) Creative Commons License

15. Co-reported respiratory adverse events in trastuzumab deruxtecan–associated interstitial lung disease: A pharmacovigilance analysis of the FAERS database

Jeral Evinç S., Eyüpler Akmercan Ç., Birsin Z., Cebeci S., Çerme E., Aliyev V., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.1, sa.1, ss.1-9, 2026 (SCI-Expanded, Scopus)

16. Hemophagocytic Lymphohistiocytosis Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of Spontaneous Reports

Güzel S. S., Tay ., Çiçek E., Jeral Evinç S., Atal S., Papila Ç., et al.
CANCERS , cilt.18, ss.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

17. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study

Birsin Z., Güren A. K., Aliyev V., Guliyev M., Jeral S., Cebeci S., et al.
BREAST CANCER: TARGETS AND THERAPY , cilt.Volume 18, ss.1-13, 2026 (SCI-Expanded, Scopus) Creative Commons License

18. Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change

Günaltılı M., Guliyev M., Birsin Z., Çerme E., Aliyev V., Abbasov H., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.8, ss.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

19. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors

Aliyev V., Güren A. K., Guliyev M., Birsin ., Günaltılı M., Fidan M. C., et al.
MEDICINA (KAUNAS, LITHUANIA) , cilt.62, sa.3, ss.11-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

20. Diagnostic utility and discriminative ability of cholesterol-modified prognostic nutritional index and inflammatory indicators in colorectal cancer: a retrospective case-control study

Papila B., Durmus S., Guliyev M., Alan Ö., Demirci N. S., Gelisgen R., et al.
SCIENTIFIC REPORTS , cilt.1, ss.1-27, 2026 (SCI-Expanded, Scopus)

21. Real-world efficacy of ramucirumab plus paclitaxel with or without nivolumabin patients with advanced gastric and gastroesophageal junction cancers

Köylü B., Kıkılı C. İ., Kemik ., Demir N., Alan Ö., Laçin Ş., et al.
Annals of Medical Research , cilt.2026, sa.33, ss.91-98, 2026 (TRDizin) Creative Commons License

22. Inflammatory and Nutritional Indices as Prognostic Markers in Locally Advanced Gastric Cancer Treated with Neoadjuvant FLOT: A Retrospective Multicenter Study

Yolcu S. T., Günaltılı M., Ayaz Yolcu E., Güzel S. S., ¸Sengül N., Atcı M. M., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.7, ss.1-19, 2026 (SCI-Expanded, Scopus) Creative Commons License

23. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

Yıldız S., Demir H., Özüdoğru T., Günenç D., Gökdere Z. S., Arvas H., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.6, ss.1-17, 2026 (SCI-Expanded, Scopus) Creative Commons License

24. Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group.

Şahin G., Tüzün E. K., Güzel H. G., Guliyev M., Dişli A. K., Yazıcı M., et al.
International journal of cancer , cilt.158, ss.1067-1079, 2026 (SCI-Expanded, Scopus) identifier identifier identifier

25. Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study.

Sucuoğlu İşleyen Z., Seçmeler Ş., Sakin A., Cihan Ş., Beşiroğlu M., Kahraman S., et al.
BMC cancer , 2026 (SCI-Expanded, Scopus) identifier

26. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

Koksal B., Yildirim H. C., Guven D. C., Kose F., Koymen G., Ozdemir O., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.15, sa.4, ss.1-14, 2026 (SCI-Expanded, Scopus) Creative Commons License

27. Bevacizumab combined with irinotecan or temozolomide in recurrent glioblastoma: a Turkish Oncology Group (TOG) study

Akbas S., Alan Ö., Yildiz O., Karakurt M., Yildirim E. C., Colak R., et al.
JOURNAL OF NEURO-ONCOLOGY , cilt.176, sa.2, ss.1-9, 2026 (SCI-Expanded, Scopus)

28. Long-Term Oncological Outcomes for Locally Advanced Rectal Cancer Patients with Pathological Complete Response After Neoadjuvant Chemoradiotherapy: A Turkish Oncology Group Study

Uysal M., Saglam S., Beypınar İ., Saglam E. K., Mammadov E., Ocak B., et al.
CANCER INVESTIGATION , cilt.44, sa.2, ss.127-135, 2026 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

29. Prognostic Factors and Real-World Outcomes in Patients Aged 65 Years and Older with Stage II and III Colon Cancer

Birsin Z., Cebeci S., Jeral S., Aliyev V., Demirci N. S., Alan Ö.
Eurasian Journal of Medical Investigation , cilt.9, sa.4, ss.1-13, 2026 (TRDizin) Creative Commons License

30. Stage II colon cancer: does ChatGPT recommend more intensive adjuvant therapy? A comparison with MDT decisions.

Birsin Z., Jeral S., Cebeci S., Çerme E., Aliyev V., Günaltılı M., et al.
Future oncology (London, England) , ss.1-8, 2025 (SCI-Expanded, Scopus) identifier

31. Chronic kidney disease and denosumab in metastatic bone disease: A multicenter Turkish cohort study on severe hypocalcemia, skeletal events, and survival

Ellez H. İ., Semiz H. S., Ekinci F., Erdoğan A. P., Kuş F., Karataş F., et al.
JOURNAL OF BONE ONCOLOGY , cilt.55, ss.1-7, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

32. Independent Prognostic Role of Postoperative Carcinoembryonic Antigen in Stage II Colon Cancer

Birsin Z., Aliyev V., Jeral N. S., Cebeci S., Abbasov H., Demirci N. S., et al.
Cerrahpaşa Medical Journal , cilt.2025, sa.49, ss.1-8, 2025 (TRDizin) Creative Commons License

33. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Efil S. C., Kus F., Koylu B., Durukan B. M., Bayram S., Guzel H. G., et al.
CANCERS , cilt.18, sa.1, ss.1-21, 2025 (SCI-Expanded, Scopus) Creative Commons License

34. Thrombotic Microangiopathy Associated with Etoposide in Metastatic Lung Cancer: Diagnostic and Therapeutic Challenges

Güzel S. S., Çakan Z. K., Karalı O., Çavlı H. B., Demirci N. S., Alan Ö.
Journal of oncological sciences , cilt.11, sa.2, ss.1-6, 2025 (Scopus, TRDizin) Creative Commons License

35. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study.

Efil S. C., Bilgin B., Bilgetekin I., Helvaci K., Sakalar T., Nayir E., et al.
Scientific reports , cilt.15, sa.1, ss.36175, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

36. Immune Checkpoint Inhibitor Associated Kidney Transplant Rejection: A Real World Pharmacovigilance Analysis Using the FAERS Database

Mütiş Alan A., Alan Ö.
The Eurasian Journal of Medical Investigation , cilt.9, sa.3, ss.176-181, 2025 (TRDizin) Creative Commons License

37. Inflammatory and Nutritional Markers Predicting Pathological Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Multicenter Real-World Study

Birsin Z., Nazli I., Alkan O., ODABAŞI BÜKÜN H., Gunaltili M., Cerme E., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.20, 2025 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

38. Impact of Blood Type on Treatment Response and Survival in HER2-Negative Metastatic Gastric Cancer

Yıldırım S., Alan Ö., Türkoğlu E., Sariyar Busery N., Doğan A., Akdağ G., et al.
Cerrahpaşa Medical Journal , cilt.49, sa.0042, ss.1-6, 2025 (TRDizin) Creative Commons License

39. Prognostic impact of pan-immune-inflammation value and prognostic nutritional index in metastatic colorectal cancer patients treated with regorafenib

Yıldırım S., Alan Ö., Yıldız H. Ş., Doğan A., Ay Ersoy S., Odabaş H.
THE EUROPEAN RESEARCH JOURNAL , cilt.1, sa.11, ss.1-11, 2025 (TRDizin) Creative Commons License

40. Palbociclib in liposarcoma: real-world multicenter data from the Turkish Oncology Group (TOG).

Kus F., Yildirim H. C., Bayram D., Bal O., Sahin G., Ugrakli M., et al.
Journal of chemotherapy (Florence, Italy) , ss.1-9, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

41. Evaluating the Prognostic Role of Pan-Immune-Inflammation Value in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab

Guliyev M., Alan Ö., Fidan M. C., Abbasov H., Cebeci S., Aliyev V., et al.
Cerrahpaşa Medical Journal , cilt.49, sa.1, ss.1-9, 2025 (TRDizin) Creative Commons License identifier

42. Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study

Birsin Z., Odabaşı Bükün H., Nazlı İ., Alkan O., Günaltılı M., Çerme E., et al.
MEDICINA (KAUNAS, LITHUANIA) , cilt.61, sa.9, ss.1-13, 2025 (SCI-Expanded, Scopus) identifier identifier identifier identifier

43. Comparative Efficacy and Cost-Effectiveness of Denosumab Versus Zoledronic Acid in Cancer Patients with Bone Metastases

Aliyev V., Guliyev M., Gunaltili M., Fidan M. C., Cerme E., Abbasov H., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.18, 2025 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

44. Low Skeletal Muscle Index as a Predictor of Pathological Complete Response in HER-2 Positive and Triple-Negative Breast Cancer

Günaltılı M., Guliyev M., Fidan M. C., Birsin Z., Çerme E., Aliyev V., et al.
MEDICINA (KAUNAS, LITHUANIA) , cilt.61, sa.9, ss.1-13, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

45. The Impact of Low HER2 expression on clinicopathological features and clinical outcomes in patients with metastatic gastric cancer

Guliyev M., Safarov S., Günaltılı M., Fidan M. C., Çerme E., Alkan Şen G., et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY , cilt.1, ss.1-22, 2025 (SCI-Expanded, Scopus) identifier identifier identifier identifier

46. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis from the Turkish Oncology Group

Telli T. A., Tatlı A. M., Alan Ö., Keskin G. Y., Karadurmuş N., Karakaya S., et al.
CLINICAL LUNG CANCER , cilt.1, sa.1, ss.1-30, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

47. First-Line Chemotherapy Versus CDK4/6 Inhibitors in HR-Positive, HER2-Negative Breast Cancer with Liver Metastases: A Multicenter Real-World Data

Fidan M. C., Öztürk A. E., Aydın O., Akdağ G., Türkoğlu E., Çolak R., et al.
JOURNAL OF CLINICAL MEDICINE , cilt.14, sa.13, ss.1-18, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

48. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations

Alan Ö., Akin Telli T., Akbaş S., Işık S., Çavdar E., Karaboyun K., et al.
MEDICINA (KAUNAS, LITHUANIA) , cilt.61, sa.7, ss.1-13, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

49. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis.

Yıldırım S., Başoğlu T., Doğan A., Akdağ G., Kınıkoğlu O., Topal A., et al.
BMC cancer , cilt.25, sa.1, ss.833, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

50. Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach

Alan Ö., Altıntaş Y. E., Bayram Kuvvet B., Duman A., Bülbül M. C., Çeleb O., et al.
Journal of oncological sciences , cilt.11, sa.1, ss.50-54, 2025 (TRDizin) Creative Commons License

51. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., Yaslıkaya Ş., Mıldanoglu M. M., Coskun A., Ercan Uzundal D., Sahin T. K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.1, sa.1, ss.1-9, 2025 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier identifier identifier

52. Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer

Guliyev M., Alan Ö., Safarov S., Alkan Şen G., Günaltılı M., Fidan M. C., et al.
Journal of oncological sciences , cilt.11, sa.1, ss.14-21, 2025 (TRDizin) Creative Commons License

53. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors.

Güren A. K., Guliyev M., Alan Ö., Çadırci K., Belevi İ. N., Gültürk İ., et al.
Journal of clinical medicine , cilt.14, sa.4, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

54. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.
CANCERS , cilt.17, sa.4, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

55. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.

Majidova N., Arak H., Ozalp F. R., Bas O., Koker G. O., Ozmarasalı E. B., et al.
Scientific reports , cilt.15, sa.1, ss.3200, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

56. Immunotherapy-related secondary hemophagocytosis in a glioblastoma patient: response to cytokine-directed therapy

Alan Ö., Bulbul M. C., Enlice M. A., Mandel N. M.
IMMUNOTHERAPY , cilt.17, sa.1, ss.11-17, 2025 (SCI-Expanded, Scopus) identifier identifier identifier identifier

57. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

Yildirim S., Dogan A., Akdag G., Yüksel Yasar Z., Bal H., Kinikoglu O., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus) identifier identifier

58. Nivolumab, Ramucirumab and Paclitaxel Combination as Second Line Therapy for Advanced Stage Gastric Cancer

Akbaş S., Alan Ö., Bayram Kuvvet B., Laçin Ş., Köylü B., Selçukbiricik F.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.8, sa.4, ss.488-495, 2024 (ESCI, TRDizin) Creative Commons License

59. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients.

Guliyev M., Alan Ö., Günaltılı M., Safarov S., Fidan M. C., Alkan Şen G., et al.
Medicina (Kaunas, Lithuania) , cilt.60, sa.12, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

60. Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients.

Peker Eyüboğlu İ., Koca S., Çelik B., Güllü Amuran G., Uğurlu M. Ü., Alan Ö., et al.
International journal of breast cancer , cilt.2024, ss.6117394, 2024 (ESCI) identifier

61. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

Isik D., Alan Ö., Akdağ G., Yildirim S., Kınıkoğlu O., Altintas Y. E., et al.
Journal of Clinical Medicine , cilt.13, sa.20, 2024 (SCI-Expanded, Scopus) identifier identifier

62. Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy.

Arıkan R., Demircioğlu Ö., Özgüven S., Demircan N. C., Alan Ö., Telli T. A., et al.
Indian journal of cancer , cilt.61, sa.4, ss.789-796, 2024 (SCI-Expanded, Scopus) identifier

63. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜVEN D. C., Koksal B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

64. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

Yildirim S., Alan Ö., Yuksel Yasar Z., Kaya T., Akdag G., Kinikoglu O., et al.
Medicina (Lithuania) , cilt.60, sa.8, 2024 (SCI-Expanded, Scopus) identifier identifier

65. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.
Journal of oncological sciences , cilt.10, sa.2, ss.89-96, 2024 (TRDizin) identifier identifier

66. A propensity score-matched comparison of neoadjuvant chemoradiotherapy with cisplatin-5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

Gürler F., Tay F., Sucuoğlu İşleyen Z., Yerlikaya T., Hendem E., Esen S. A., et al.
Cancer Medicine , cilt.13, sa.14, 2024 (SCI-Expanded, Scopus) identifier identifier

67. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.
JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus) identifier

68. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

Akdag G., Yildirim S., Dogan A., Yasar Z. Y., Bal H., Kinikoglu O., et al.
Chemotherapy , cilt.69, sa.3, ss.141-149, 2024 (SCI-Expanded, Scopus) identifier identifier

69. Prognostic scores in pulmonary large cell neuroendocrine carcinoma: A retrospective cohort study

Akdag G., Alan Ö., Dogan A., Yildirim S., Kinikoglu O., Batu A., et al.
Heliyon , cilt.10, sa.3, 2024 (SCI-Expanded, Scopus) identifier

70. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Almuradova E., Seyyar M., Arak H., Tamer F., Kefeli U., Koca S., et al.
International Journal of Cancer , cilt.154, sa.4, ss.692-700, 2024 (SCI-Expanded, Scopus) identifier identifier

71. Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT

Çelik B., PEKER EYÜBOĞLU İ., Koca S., Ümit Uğurlu M., Alan Ö., GÜLLÜ AMURAN G., et al.
Turkish Journal of Medical Sciences , cilt.54, sa.4, ss.652-665, 2024 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier

72. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Avci O., Iriagac Y., Cavdar E., Karaboyun K., Araz M., Sakalar T., et al.
JOURNAL OF GERIATRIC ONCOLOGY , cilt.14, sa.8, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

73. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Ünal Ç., AZİZY A., KARABULUT S., TAŞTEKİN D., AKYILDIZ A., YAŞAR S., et al.
The oncologist , cilt.28, sa.10, ss.875-884, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

74. Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

Akdag G., Alan Ö., Dogan A., Yuksel Z., Yildirim S., Kinikoglu O., et al.
World Journal of Urology , cilt.41, sa.8, ss.2201-2207, 2023 (SCI-Expanded, Scopus) identifier identifier

75. Major and minor salivary gland cancers: A multicenter retrospective study.

Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.
Head & neck , cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

76. The Prognostic and Predictive role of DR70 immunoassay in Patients with Advanced (Metastatic) Breast Cancer

KOCA S., BABACAN N. A., ÖKTEN İ. N., TELLİ T. A., ALAN Ö., Aktas B., et al.
Eurasian Journal of Medical Investigation , cilt.7, sa.2, ss.170-174, 2023 (TRDizin) identifier

77. Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities

Telli T. A., Alan Ö., Demircan N. C., Sariyar N., Arikan R., Basoglu T., et al.
Orthopaedics and Traumatology: Surgery and Research , cilt.109, sa.3, 2023 (SCI-Expanded, Scopus) identifier identifier

78. Evaluation of the effectiveness of drug-eluting transarterial chemoebolization in hepatocellular carcinoma

Alan A. M., Alan Ö., Asadov R., DEMİRTAŞ C. Ö., KANİ H. T., Yumuk P. F., et al.
Hepatology Forum , cilt.4, sa.2, ss.53-60, 2023 (Scopus) identifier identifier

79. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Almuradova E., Basoglu T., Nayir E., Bayram E., Paydas S., Gokmen I., et al.
Neoplasma , cilt.70, sa.1, ss.158-165, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

80. Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study

Gursoy P., Tatli A. M., Erdem D., Goker E., Celik E., Demirci N. S., et al.
Journal of Cancer Research and Clinical Oncology , cilt.149, sa.2, ss.865-875, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

81. Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Unal C., Selcuk N. A., Biricik F. S., Alan Ö., Ordu C., Selvi O., et al.
Eurasian Journal of Medicine and Oncology , cilt.7, sa.3, ss.232-242, 2023 (ESCI, Scopus, TRDizin) identifier identifier

82. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study

Başoğlu T., Sakin A., Erol C., Özden E., Çabuk D., Çılbır E., et al.
Journal of Chemotherapy , cilt.35, sa.2, ss.142-149, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

83. Clinical and inflammation marker features of cancer patients with COVID-19: data of Istanbul, Turkey multicenter cancer patients (2020–2022)

Ünal Ç., Tunçer G., Çopur B., Pilanci K. N., Okutur K. S., Yararbaş K., et al.
Current Medical Research and Opinion , cilt.39, sa.7, ss.987-996, 2023 (SCI-Expanded, Scopus) identifier identifier

84. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment

Telli T. A., ÖZGÜVEN S., ALAN Ö., Filizoglu N., ÖZTÜRK M. S., Sariyar N., et al.
ANNALS OF NUCLEAR MEDICINE , cilt.36, sa.11, ss.964-975, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

85. Prognostic factors of perioperative FLOT regimen in operable gastric and gastroesophageal junction tumors: real-life data (Turkish Oncology Group)

Erol C., Sakin A., Başoglu T., Özden E., ÇABUK D., Doğan M., et al.
Turkish Journal of Medical Sciences , cilt.52, sa.4, ss.1022-1032, 2022 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier identifier

86. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy

Telli T. A., ÖZTÜRK M. S., Alan Ö., Hasanov R., KÖSTEK O., Arikan R., et al.
Future Oncology , cilt.18, sa.22, ss.2425-2439, 2022 (SCI-Expanded, Scopus) identifier identifier

87. İleri Evre Gastrointestinal Kanserli Hastalarda Fibrin ile İlişkili Yeni Bir Biyobelirteç Olan Serum DR-70 Düzeyinin Prognostik ve Prediktif Değeri

ÇETİN M., BABACAN N. A., ALAN Ö., OZTURK M. A., HASANOV R., KOCA S., et al.
Namık Kemal Tıp Dergisi , cilt.10, sa.1, ss.74-79, 2022 (TRDizin) identifier

88. Association of Pre-treatment Sarcopenia with Side Effects and Prognosis in Non-small Cell Lung Cancer Patients Receiving Erlotinib

Demircan N. C., Engür C. Ö., Akin Telli T., Başoğlu T., Arikan R., Yaşar A., et al.
Turk Onkoloji Dergisi , cilt.37, sa.4, ss.379-387, 2022 (ESCI, Scopus, TRDizin) Creative Commons License identifier identifier

89. Impact of prognostic nutritional index on survival in recurrent glioblastoma Impacto de Prognostic Nutritional Index en la supervivencia de los glioblastomas recurrentes

Alan Ö., Telli T. A., Basoğlu T., Arikan R., Demircan N. C., Ercelep O., et al.
Neurocirugia , cilt.33, sa.1, ss.15-21, 2022 (SCI-Expanded, Scopus) identifier identifier

90. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma

Telli T. A., BUĞDAYCI O., Alan Ö., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer , cilt.74, sa.7, ss.2499-2507, 2022 (SCI-Expanded, Scopus) identifier identifier

91. The effect of preoperative prognostic nutritional index on outcome in glioblastoma multiforme patients

Oyman A., Işık S., Eröz S., Özçelik M., Cil I., Alan Ö., et al.
The Journal of Surgery and Medicine (JOSAM , cilt.6, sa.2, ss.177-180, 2022 (Hakemli Dergi) Creative Commons License

92. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Esen S. A., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian Journal of Basic Medical Sciences , cilt.22, sa.5, ss.818-825, 2022 (SCI-Expanded, Scopus) identifier identifier

93. Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer

Yakup I., Eyyup C., Kubilay K., Okan A., Ozkan A., Halil T., et al.
Bratislava Medical Journal , cilt.123, sa.6, ss.401-407, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

94. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

95. Differences in PET/CT standardized uptake values involvement and survival compared to histologic subtypes of lung adenocarcinoma

Ercelep O., Alan Ö., Telli T. A., Tuylu T. B., Arıkan R., Demircan N. C., et al.
Tumori , cilt.107, sa.3, ss.231-237, 2021 (SCI-Expanded, Scopus) identifier identifier

96. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

AK N., ÖZKAN B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., et al.
JOURNAL OF BUON , cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

97. Clinicopathologic and Radiologic Characteristics of Pleomorphic Lobular Breast Cancer

ARIKAN R., TELLİ T. A., ALAN Ö., DEMİRCAN N. C., BAŞOĞLU T., ERCELEP Ö., et al.
Eurasian Journal of Medical Investigation , cilt.5, sa.1, ss.148-152, 2021 (TRDizin) Creative Commons License identifier

98. Preoperative Prognostic Nutritional Index is a Strong Predictorof Survival in Patients with Localized Soft Tissue Sarcoma

TELLİ T. A., SARIYER N., ALAN Ö., DEMİRCAN N. C., IŞIK S., ARIKAN R., et al.
Eurasian Journal of Medical Investigation , cilt.5, sa.2, ss.256-262, 2021 (TRDizin) identifier

99. Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience

Alan Ö., Telli T. A., Tuylu T. B., Arikan R., Demircan N. C., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , cilt.27, sa.2, ss.329-339, 2021 (SCI-Expanded, Scopus) identifier identifier

100. Clinicopathological features, treatment outcomes, and prognostic factors in adrenocortical carcinoma: A single-center experience

Demircan N. C., Akin Telli T., Başoğlu T., Arikan R., Yaşar A., Çelebi A., et al.
Journal of Oncological Science , cilt.7, sa.3, ss.133-138, 2021 (Scopus, TRDizin) Creative Commons License identifier

101. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.
CANCER INVESTIGATION , cilt.39, ss.473-481, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

102. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer

Demirelli B., Babacan N. A., Ercelep Ö., Öztürk M. A., Kaya S., Tanrıkulu E., et al.
Nutrition and Cancer , cilt.73, sa.2, ss.230-238, 2021 (SCI-Expanded, Scopus) identifier identifier

103. OPERE ERKEN EVRE AKCİĞER KANSERİ HASTALARINDA PROGNOSTİK FAKTÖRLER RETROSPEKTİF TEK MERKEZ SONUÇLARI

ALAN Ö., ERCELEP Ö., TELLİ T. A., TANRIKULU E. Ş., HASANOV R., BASOGLU T., et al.
Namık Kemal Tıp Dergisi , cilt.8, sa.3, ss.376-382, 2020 (TRDizin) identifier

104. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Akdeniz N., Küçüköner M., Kaplan M. A., Urakçı Z., Karhan O., Sezgin Y., et al.
International Journal of Clinical Oncology , cilt.25, sa.12, ss.2015-2024, 2020 (SCI-Expanded, Scopus) identifier identifier

105. Worse patient–physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yaşar A., Zeynep Gülsüm G., Gürbüz M., Başoğlu T., Sezgin Göksu S., et al.
European Journal of Cancer Care , cilt.29, sa.6, 2020 (SCI-Expanded, SSCI, Scopus) identifier identifier

106. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial

DEMİR A., DEMİR G., ER Ö., ERALP Y., ULUÇ B. O., UYSAL Ö. S., et al.
Balkan Medical Journal , cilt.37, sa.2, ss.104-107, 2020 (SCI-Expanded, Scopus, TRDizin) identifier identifier

107. VEGF-VEGFR pathway seems to be the best target in hepatic epithelioid hemangioendothelioma: A case series with review of the literature

Telli T. A., Okten I. N., Tuylu T. B., Demircan N. C., Arikan R., Alan Ö., et al.
Current Problems in Cancer , cilt.44, sa.5, 2020 (SCI-Expanded, Scopus) identifier identifier

108. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?

Alan Ö., Akin Telli T., Aktas B., Koca S., Ökten I. N., Hasanov R., et al.
World Journal of Surgical Oncology , cilt.18, sa.1, 2020 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

109. Comparison of Seventh and Eighth Editions of TNM Staging Classification and Evaluation of Survivals in Operated Non-Small Cell Lung Carcinomas: Single Center Experience

ERCELEP Ö., ALAN Ö., TELLİ T. A., TÜYLÜ T. B., ARIKAN R., DEMİRCAN N. C., et al.
Eurasian Journal of Medical Investigation , cilt.4, sa.2, ss.243-246, 2020 (TRDizin) identifier

110. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment

Alan Ö., Telli T. A., Basoğlu T., Arikan R., Demircan N. C., Ercelep O., et al.
Clinical Neurology and Neurosurgery , cilt.196, 2020 (SCI-Expanded, Scopus) identifier identifier

111. The Relationship Between the Prognostic Nutritional Index and Overall Survival in Elderly Patients with Epithelial Ovarian Cancer

DEMİR A., ALAN Ö., KOCA S., SÜRMELİ H.
Eurasian Journal of Medical Investigation , cilt.4, sa.2, ss.269-273, 2020 (TRDizin) identifier

112. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy

AKKİPRİK M., Koca S., UĞURLU M. Ü., Ekren R., PEKER EYÜBOĞLU İ., Alan Ö., et al.
Clinical Breast Cancer , cilt.20, sa.4, ss.332, 2020 (SCI-Expanded, Scopus) identifier identifier

113. Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib

Demircan N. C., Alan Ö., Başoğlu Tüylü T., Akın Telli T., Arıkan R., Çiçek F. C., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.5, ss.1147-1155, 2020 (SCI-Expanded, Scopus) identifier identifier

114. A case of spontaneous tumor lysis syndrome in extensive-stage small-cell lung cancer: A rare oncologic emergency

Alan A., Alan Ö.
TURKISH JOURNAL OF EMERGENCY MEDICINE , cilt.20, sa.3, ss.142-145, 2020 (ESCI, Scopus) identifier identifier identifier

115. A rare case of primary rectal choriocarcinoma and review of the literature

Telli T. A., Demircan N. C., Alan Ö., Tuylu T. B., Arikan R., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.4, ss.989-994, 2020 (SCI-Expanded, Scopus) identifier identifier

116. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature

Alan Ö., Kuzhan O., Koca S., Telli T. A., Basoglu T., Ercelep O., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.4, ss.1011-1018, 2020 (SCI-Expanded, Scopus) identifier identifier

117. Early PSA response to antiandrogen therapy in metastatic castration-resistant prostate carcinoma patients: A predictive marker for progression-free survival?

Atakan D., Ozkan A., Guve M. A., Sinan K.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.25, sa.3, ss.1625-1630, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

118. Predictive Values of Systemic Inflammation Index in Prognosis of Patients with Laryngeal Cancer

Demir A., Alan Ö., Surmeli M.
Eurasian Journal of Medicine and Oncology , cilt.4, sa.1, ss.49-53, 2020 (ESCI, Scopus, TRDizin) identifier identifier

119. Smokers having activating EGFR mutant non-small cell lung cancer might benefit from EGFR-TKI treatment – single-center experience

Ercelep Ö., Akin Telli T., Alan Ö., Hasanov R., Tanrikulu Şimşek E., Akgül Babacan N., et al.
Turk Onkoloji Dergisi , cilt.35, sa.3, ss.334-339, 2020 (ESCI, Scopus, TRDizin) Creative Commons License identifier

120. The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study

ERALP Y., AK N., Yilmazbayhan D., ÖZKAN B., FERHATOĞLU F., Demirkazik A., et al.
JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded, Scopus) identifier

121. Is Laboratory Prognostic Index a Valuable Prognostic Index for Malignant Pleural Mesothelioma?

Tuylu T. B., Demircan N. C., Arikan R., Telli T. A., ALAN Ö., Ercelep O., et al.
JOURNAL OF THORACIC ONCOLOGY , sa.10, 2019 (SCI-Expanded, Scopus) identifier

122. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy

Alan Ö., Telli T. A., Ercelep O., Hasanov R., Simsek E. T., Mutis A., et al.
CURRENT PROBLEMS IN CANCER , cilt.43, sa.4, ss.308-311, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

123. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.

Demircan N., Dane F., Ozturk M. A., Babacan N. A., Besiroglu M., Kaya S., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.24, sa.4, ss.1494-1500, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

124. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer

Ercelep O., ALAN Ö., Sahin D., Telli T. A., Salva H., Tuylu T. B., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY , cilt.21, sa.4, ss.499-504, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

125. Rektum Kanserinin Prognozunu Öngermede Ortalama Trombosit Hacmi (MPV)'nin Rolü

DEMİR A., ALAN Ö.
Namık Kemal Tıp Dergisi , cilt.7, sa.3, ss.279-286, 2019 (TRDizin) identifier

126. Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment

Demir A., Alan Ö., Oruc E.
World Journal of Surgical Oncology , cilt.17, sa.1, 2019 (SCI-Expanded, Scopus) identifier identifier

127. Is Preoperative SUV(Max) of Primary Tumor a Predictor of Relapse for Operable Non-Small Cell Lung Cancer?

ALAN Ö., Ercelep O., Telli T. A., Tuylu T. B., ÖNEŞ T., BOZKURTLAR E., et al.
JOURNAL OF THORACIC ONCOLOGY , sa.10, 2018 (SCI-Expanded, Scopus) identifier

128. Chordoma: A case series and review of the literature

Alan Ö., Akin Telli T., Ercelep O., Tanrikulu Simsek E., Basoglu Tuylu T., Mutis A., et al.
Journal of Medical Case Reports , cilt.12, sa.1, 2018 (Scopus) identifier identifier

129. Prognostic factors in early stage lung cancer patients: Retrospective single center data.

ALAN Ö., Ercelep O., Telli T. A., Hasanov R., Tuylu T. B., Simsek E. T., et al.
JOURNAL OF CLINICAL ONCOLOGY , sa.15, 2018 (SCI-Expanded, Scopus) identifier

130. Smokers Having Activating EGFR Mutant Non-Small Cell Lung Cancer Might Benefit from EGFR-TKI Treatment - Single Center Experience

Ercelep O., Telli T., ALAN Ö., Hasanov R., Simsek E., Halil S., et al.
JOURNAL OF THORACIC ONCOLOGY , sa.11, 2017 (SCI-Expanded, Scopus) identifier

131. A Retrospective Review of Small Cell Lung Cancer (SCLC) Patients Treated at Marmara University Hospital

Eris A., ÖZTÜRK M., Dane F., BOZKURTLAR E., KOCAKAYA D., ALAN Ö., et al.
JOURNAL OF THORACIC ONCOLOGY , sa.11, 2017 (SCI-Expanded, Scopus) identifier

132. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.

Kaya S., Aktas B., Tanrikulu Sismek E., Akif Ozturk M., Dede F., Kaya H., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology , cilt.22, sa.5, ss.1191-1198, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

133. Evaluation of non-invasive diagnostic methods as indicators of fibrosis in patients with nonalcoholic fatty liver disease

Atay K., Canbakan B., Alan Ö., Koroglu E., Hatemi I., Kepil N., et al.
BIOMEDICAL RESEARCH-INDIA , sa.2, ss.565-570, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 40

1. 543eP - Can baseline immune inflammation predict outcomes? The role of the pan-immune inflammation value in HR-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors

Cebeci S., Birsin Z., Jeral S., Abbasov H., Aliyev V., Cerme E., et al.
ESMO BREAST CANCER 2026, Berlin, Almanya, 6 - 08 Mayıs 2026, ss.1, (Özet Bildiri)

2. CDK4/6 INHIBITÖRLERI ILE ILIŞKILI RENAL VE ELEKTROLIT ADVERS OLAYLARIN FAERS TABANLI DISPROPORSIYONEL ANALIZI

Mütiş Alan A., Alan Ö.
Uluslararası Katılımlı 15. Güncel Böbrek Hastalıkları ve 10. Hipertansiyon, Nefroloji, Diyaliz ve Transplantasyon Kongresi, Muğla, Türkiye, 22 - 26 Nisan 2026, ss.90-91, (Özet Bildiri) Creative Commons License

3. İkili Anti-HER2 Blokajı Alan Metastatik HER2-Pozitif Meme Kanserli Hastalarda Dosetaksel Kür Sayısının Sağkalım Üzerine Etkisi

Birsin Z., Çiçek E., Demirci N. S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Türkiye, 6 - 08 Şubat 2026, ss.19-20, (Özet Bildiri)

4. Erkek Meme Kanserinde Klinikopatolojik Özellikler: Tek Merkez Deneyimi

Çiçek E., Günaltılı M., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Türkiye, 6 - 08 Şubat 2026, ss.27, (Özet Bildiri)

5. Hedefe Yönelik Uzun Yolculuk: İleri Kalp Yetmezliği Eşliğinde Metastatik HR+ Meme Kanserinde Üç Yıllık Alpelisib Başarısı

Güzeş S. S., Alan Ö., Demirci N. S.
6.Meme Kanseri Sempozyumu, İstanbul, Türkiye, 6 - 08 Şubat 2026, ss.18-19, (Özet Bildiri)

6. Meme Kanseri Hastalarında Alpelisib ve Capivasertib Kullanımına bağlı Advers Olay Profillerinin FAERS Tabanlı Karşılaştırılması: Isı Haritası ve UMAP ile Çok Boyutlu Analiz

Jeral Evinç S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Türkiye, 6 - 08 Şubat 2026, ss.20-22, (Özet Bildiri)

7. CDK4/6 İnhibitörleri ile Tedavi Edilen Metastatik Meme Kanserinde PIV Skoru Prognostik Bir Belirteç Midir?

Cebeci S., Birsin Z., Jeral Evinç N. S., Alan Ö.
6.Meme Kanseri Sempozyumu, İstanbul, Türkiye, 6 - 07 Şubat 2026, ss.28, (Özet Bildiri)

8. METASTATIK MIDE KANSERINDE KLINIK, NUTRISYONEL VE İNFLAMATUAR BELIRTEÇLERIN PROGNOSTIK ÖNEMI: TEK MERKEZ RETROSPEKTIF ANALIZ

Aliyev V., Günaltılı M., Alan Ö.
9.ULUSAL İMMÜNOTERAPİ ve ONKOLOJİ KONGRESİ, Güzelyurt, Kıbrıs (Kktc), 29 Ekim - 02 Kasım 2025, ss.52-53, (Özet Bildiri) Creative Commons License

9. EVRE II KOLON KANSERI: CHATGPT DAHA YOĞUN ADJUVAN TEDAVI MI ÖNERIYOR? MDT KARARLARI ILE KARŞILAŞTIRMA

Birsin Z., Cebeci S., Jeral N. S., Alan Ö.
9.ULUSAL İMMÜNOTERAPİ ve ONKOLOJİ KONGRE, Güzelyurt, Kıbrıs (Kktc), 29 Ekim - 02 Kasım 2025, ss.36, (Özet Bildiri) Creative Commons License

10. Immune checkpoint inhibitors and hemophagocytic lymphohistiocytosis: Disproportionality analysis from FAERS

Güzel S. S., Atak S., Çiçek E., Demirci N. S., Alan Ö.
ESMO Immuno-Oncology Congress 2025, London, İngiltere, 10 - 12 Aralık 2025, ss.12, (Özet Bildiri) Creative Commons License

11. Immune-mediated upper gastrointestinal system toxicities in patients receiving immune checkpoint inhibitors: An analysis of the food and drug administration adverse event reporting system (FAERS)

Çerme E., Guliyev M., Aliyev V., Birsin Z., Günaltılı M., Fidan M. C., et al.
ESMO Immuno-Oncology Congress 2025, London, İngiltere, 10 - 12 Aralık 2025, ss.30, (Özet Bildiri) Creative Commons License

12. 3005P Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with sorafenib monotherapy: Real-world treatment patterns and clinical outcomes in Türkiye

Alan Ö.
ESMO 2025, Berlin, Almanya, 17 - 21 Ekim 2025, ss.1565, (Özet Bildiri) Creative Commons License

13. Prognostic value of systemic inflammatory markers in advanced soft tissue sarcoma patients treated with trabectedin: A retrospective analysis

Jeral S., Eyüpler Ç., Birsin Z., Nazlı İ., Güren A. K., Köylü B., et al.
ESMO 2025, Berlin, Almanya, 17 - 21 Ekim 2025, ss.1462, (Özet Bildiri) Creative Commons License

14. 2928eP Characteristics and outcomes of kidney transplant rejection associated with immune checkpoint inhibitors: A FAERS database analysis

Alan Ö., Mutis Alan A.
ESMO 2025, Berlin, Almanya, 17 Ekim - 21 Kasım 2025, ss.1535, (Özet Bildiri) Creative Commons License

15. HORMON POZITIF, HER2 NEGATIF (HR+/ HER2-) METASTATIK MEME KANSERINDE (MMK) CDK4/6 INHIBITÖRÜ TEDAVISI ALAN HASTALARDA YAŞA GÖRE TOKSISITE PROFILI VE DOZ MODIFIKASYONLARI: GERÇEK YAŞAM VERILERI

Fidan M. C., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Kıbrıs (Kktc), 1 - 05 Ekim 2025, ss.54-55, (Özet Bildiri)

16. VÜCUT KITLE İNDEKSI’NIN PCR ÜZERINE BAĞIMSIZ ETKISI: HER2-POZITIF EVRE II–III MEME KANSERINDE RETROSPEKTIF ÇALIŞMA

Birsin Z., Günaltılı M., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Kıbrıs (Kktc), 1 - 05 Ekim 2025, ss.69-70, (Özet Bildiri)

17. YATARAK TEDAVI GÖREN İLERI EVRE KANSER HASTALARINDA MORTALITEYI ÖNGÖREN FAKTÖRLER: TERSIYER MERKEZ DENEYIMI

Güzel S. S., Atak S., Çakan Z. K., Demirci N. S., Alan Ö.
2.avrasya interdisipliner onkoloji kongresi, Gazimagusa, Kıbrıs (Kktc), 1 - 05 Ekim 2025, ss.126-127, (Özet Bildiri)

18. SACITUZUMAB GOVITECAN, TRASTUZUMAB EMTANSINE VE TRASTUZUMAB DERUXTECAN ILE İLIŞKILI İNTERSTISYEL AKCIĞER HASTALIĞI: FAERS VERITABANI ANALIZI

Jeral Evinç S., Eyüpler Akmercan Ç., Cebeci S., Birsin Z., Aliyev V., Günaltılı M., et al.
2. Avrasya İnterdisipliner Onkoloji Kongresi, Gazimagusa, Kıbrıs (Kktc), 1 - 05 Ekim 2025, ss.40-41, (Özet Bildiri) Creative Commons License

19. Incidence and Frequency of Immune-Related Nephropathy in Patients Treated with Immune Checkpoint Inhibitors A FAERS Database Analysis (2020–2024)

Mütiş Alan A., Alan Ö.
62nd ERA Congress , Vienna, Avusturya, 4 - 07 Haziran 2025, ss.3330, (Özet Bildiri) Creative Commons License

20. İmmün Kontrol Noktası İnhibitörleri ile İlişkili Böbrek Nakli Rejeksiyonu Olgularının Klinik Özellikleri ve Sonuçları: FAERS Veritabanı Analizi

Mütiş Alan A., Alan Ö.
4. Cerrahpaşa İç Hastalıkları & 3. İç Hastalıkları Hemşireliği Kongresi, İstanbul, Türkiye, 5 - 07 Eylül 2025, ss.18-19, (Özet Bildiri) Creative Commons License

21. Yaygın Evre Küçük Hücreli Akciğer Kanserinde İmmunoterapinin Rolü: Atezolizumab Deneyimi

Cebeci S., Birsin Z., Jeral Evinç N. S., Alan Ö., Demirci N. S.
3. Onkolojide Yenilikler Sempozyumu, Girne, Kıbrıs (Kktc), 16 - 18 Mayıs 2025, (Yayınlanmadı)

22. IMMÜN KONTROL NOKTASI INHIBITÖRLERI ILE TEDAVI EDILEN HASTALARDA IMMÜN ILIŞKILI NEFROPATININ SIKLIĞI: BIR FAERS DATABASE ANALIZI (2020–2024)

Mütiş Alan A., Alan Ö., Dinçer M. T., Murt A., Altıparmak M. R., Seyahi N., et al.
Uluslararası Katılımlı 14. Güncel Böbrek Hastalıkları ve 9. Hipertansiyon, Nefroloji, Diyaliz ve Transplantasyon Kongresi, Muğla, Türkiye, 23 - 27 Nisan 2025, ss.85, (Özet Bildiri) Creative Commons License

23. LOKAL VE LOKAL İLERİ EVRE HER2 POZİTİF MEME KANSERİNDE NEOADJUVAN TEDAVİYE YANITI ETKİLEYEN FAKTÖRLER

Birsin Z., Cebeci S., Çiçek E., Jeral N. S., Demirci N. S., Papila Ç., et al.
12. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 23 - 27 Nisan 2025, ss.224-225, (Özet Bildiri) Creative Commons License

24. Metastatik Akciğer, Meme ve Prostat kanserli hastalarda denosumab ve zoledronik asit tedavilerinin etkinliğinin retrospektif olarak incelenmesi

Aliyev V., Alan Ö.
Hedef Kanser 2025, Girne, Kıbrıs (Kktc), 20 - 23 Mart 2025, (Yayınlanmadı) Creative Commons License

25. EFFICACY AND SAFETY OF DURVALUMAB PLUS CHEMOTHERAPY IN PATIENTS WITH ADVANCED BILIARY TRACT CANCER: A MULTICENTER REALWORD DATA FROM TURKISH ONCOLOGY GROUP

Efil S. C., Şendur M. A. N., Kuş F., Bayram S., Köylü B., Araz M., et al.
14th International Gastrointestinal Cancers Conference (IGICC2024), İstanbul, Türkiye, 28 Kasım - 01 Aralık 2024, ss.25-26, (Tam Metin Bildiri) Creative Commons License

26. PERIOPERATIVE NIVOLUMAB COMBINED WITH NEOADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA: TWO-CENTER EXPERIENCE

Köylü B., Kıkıllı İ., Selçukbiricik F., Alan Ö., Laçin Ş., Yumuk F., et al.
14th International Gastrointestinal Cancers Conference (IGICC2024)), İstanbul, Türkiye, 28 Kasım - 01 Aralık 2024, ss.6, (Tam Metin Bildiri) Creative Commons License

27. REAL-WORLD DATA ON THE EFFICACY AND SAFETY OF RAMUCIRUMAB PLUS PACLITAXEL EITHER ALONE OR IN COMBINATION WITH IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED GASTRIC ADENOCARCINOMA

Köylü B., Kıkılı İ., Alan Ö., Selçukbiricik F., Laçin Ş.
14th International Gastrointestinal Cancers Conference (IGICC2024)), İstanbul, Türkiye, 28 Kasım - 01 Aralık 2024, ss.7-8, (Tam Metin Bildiri) Creative Commons License

28. UZMAN HEKIMLERIN KANSER TARAMA PROGRAMLARI HAKKINDAKI EĞILIM ANKET SONUÇLARI/TOG ÇALIŞMASI

Özdemir Ö., Nayır E., Gürbüz M., Türk H. M., Demiray A. G., Çağlayan ., et al.
11. Türk Tıbbi Onkoloji Kongresi, Girne, Kıbrıs (Kktc), 24 - 28 Nisan 2024, ss.71-72, (Özet Bildiri) Creative Commons License

29. LOKAL ILERI GASTRIK/GASTROÖZEFAGEAL BILEŞKE ADENOKARSINOMLARINDA NEOADJUVAN IMMUNOTERAPI: İKI MERKEZ DENEYIMI

Köylü B., Selçukbiricik F., Alan Ö., Laçin Ş., Yumuk F., Kanıtez M., et al.
11. Türk Tıbbi Onkoloji Kongresi’, Girne, Kıbrıs (Kktc), 24 - 28 Nisan 2024, ss.60-61, (Özet Bildiri) Creative Commons License

30. ERIŞKIN NÖROBLASTOM VAKASI-NADIR BIR OLGU SUNUMU

Alan Ö., Bayram Kuvvet B., Altıntaş Y. E., Koçak S., Selçukbiricik F.
10. Türk Tıbbi Onkoloji Kongresi’, Antalya, Türkiye, 26 - 30 Nisan 2023, ss.124-125, (Özet Bildiri) Creative Commons License

31. İMMUNOTERAPI İLIŞKILI NÖROLOJIK YAN ETKILERIN DEĞERLENDIRILMESI: TEK MERKEZ DENEYIMI

Altıntaş Y. E., Bayram Kuvvet ., Çelebi O., Koçak S., Bülbül M. C., Alan Ö., et al.
10. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 26 - 30 Nisan 2023, ss.46-47, (Tam Metin Bildiri) Creative Commons License

32. GASTROINTESTINAL TÜMÖRLERDE MULTIDISIPLINER TÜMÖR KONSEYI SONUÇLARI TEK MERKEZ DENEYIM

Bayram Kuvvet B., Alan Ö., Akbaş ., Celayir M., Babashov F., Erel ., et al.
10. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 26 - 30 Nisan 2023, ss.47, (Tam Metin Bildiri) Creative Commons License

33. Does insulin resistance predict complete response in breast cancer patients who underwent neoadjuvant treatment?

ALAN Ö., Telli T. A., Aktas B., Koca S., Okten I. N., Tuylu T. B., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, (Özet Bildiri) identifier

34. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey

Demirci U., GÖKMEN E., Eralp Y., Gunduz S., SEZGİN GÖKSU S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, (Özet Bildiri) identifier

35. Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non-small cell lung cancer

Isikogan A., Akdeniz N., Kucukoner M., Kaplan M. A., Urakci Z., Karhan O., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.595, (Özet Bildiri) identifier

36. Neoadjuvant treatment in patients with locally advanced gastric cancer.

GÜMÜŞ M., Kaya S., Eris S., ALAN Ö., Telli T. A., Okten I. N., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 17 - 19 Ocak 2019, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

37. The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Kilickap S., ÖLMEZ Ö. F., ÇİÇİN İ., Demirci U., ALAN Ö., ÇABUK D., et al.
43rd ESMO Congress (ESMO), Munich, Almanya, 19 - 23 Ekim 2018, ss.505, (Özet Bildiri) identifier

38. Modified Glasgow prognostic score, prognostic nutritional index and ECOG score could be new prognostic factors for survival in metastatic gastric cancer

Demirelli B., Babacan N., Koca S., Uzun B. N., Ercelep O., ÖZTÜRK M., et al.
42nd European-Society-for-Medical-Oncology Congress (ESMO), Madrid, İspanya, 8 - 12 Eylül 2017, (Özet Bildiri) identifier

39. Analysis of survival and prognostic factors in metastatic colorectal cancer patients treated with first line bevacizumab.

Demircan N., Dane F., Ozturk M. A., Besiroglu M., Babacan N., Kaya S., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

40. Changes in 18F-FDG-PET/CT tumor metabolism and prediction of pathologic complete response rates after neoadjuvant chemotherapy in hormone-positive breast cancer.

Kaya S., Aktas B., Simsek E. T., Ozturk M. A., DEDE F., Kaya H., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, (Özet Bildiri) identifier
Kitaplar 5

1. Akciğer Kanserleri

Alan Ö., Yumuk P. F.
İç Hastalıkları, Dr. Gürler İLİÇİN,Kadir BİBEROĞLU,Gültekin SÜLEYMANLAR,Serhat ÜNAL, Editör, Güneş Kitabevi, Ankara, ss.1693-1698, 2024 Creative Commons License

2. Parotisin Malign Tümörlerinde Adjuvan Tedavi Yaklaşımları Adjuvant Treatment for Malignant Parotid Tumors

Atasoy B. M., Üçüncü Kefeli A., Alan Ö.
KulaK Burun Boğaz ÖZEL KONULAR, Günter HAFIZ,Selçuk GÜNEŞ, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.70-76, 2021 Creative Commons License

3. KANSER TEDAVİSİNDE İMMUNOTERAPİ

Alan Ö.
Onkolojik Aciller , Tarkan Yetişyiğit,Serhat Örün, Editör, Akademisyen Yayınevi Kitabevi, İstanbul, ss.67-77, 2020 Creative Commons License

4. GlioblastomdaNüksHastalıkta SistemikTedaviSeçenekleri-

Alan Ö., Yumuk F.
Erişkin Santral Sinir Sistemi Tümörleri, PerranFulden YUMUK, Editör, Türkiye Klinikleri Yayınevi, Ankara, ss.61-65, 2019 Creative Commons License

5. MESANE KANSERİNİN NEOADJUVAN/ADJUVAN TEDAVİSİNDE GÜNCEL DURUM

Alan Ö., Öztürk M. A.
Mesane ve Üst Üriner Sistem Kanserleri, Kamil Çam, Editör, Türkiye Kanserle Savaş Vakfı, Ankara, ss.84-86, 2016 Creative Commons License
Metrikler

Yayın

180

Yayın (WoS)

119

Yayın (Scopus)

112

Atıf (WoS)

137

H-İndeks (WoS)

7

Atıf (Scopus)

448

H-İndeks (Scopus)

10

Atıf (Scholar)

10

H-İndeks (Scholar)

2

Atıf (TrDizin)

4

H-İndeks (TrDizin)

1

Atıf (Sobiad)

1

H-İndeks (Sobiad)

1

Atıf (Diğer Toplam)

4

Toplam Atıf Sayısı

146

Tez Danışmanlığı

1

Açık Erişim

66
BM Sürdürülebilir Kalkınma Amaçları